Verrica to Announce Q2 Financials and VP-315 Phase 2 Trial Results on August 14, 2024

Verrica Pharmaceuticals Inc., a company dedicated to dermatology therapeutics, has announced a conference call and live webcast scheduled for 8:30 a.m. ET on Wednesday, August 14, 2024. During this event, the company will discuss its financial results for the second quarter ending June 30, 2024, and provide an overview of the topline results from Part 2 of the Phase 2 trial of VP-315, a treatment for basal cell carcinoma. Interested individuals can join the live call by dialing the provided telephone numbers and using the conference ID: VERRICA. Participants are encouraged to dial in 10 minutes before the call to register. Additionally, a live audio webcast will be available on Verrica's website, and a replay will be archived for 90 days post-event.

Verrica Pharmaceuticals Inc. is focused on developing medications for skin diseases that necessitate medical intervention. On July 21, 2023, the company achieved a significant milestone when YCANTH® (cantharidin) was approved by the FDA as the first treatment for molluscum contagiosum. This highly contagious viral skin infection affects about 6 million people in the United States, with a significant number being children. YCANTH (VP-102) is also being developed for treating common warts and external genital warts, addressing two major unmet needs in medical dermatology.

In addition to YCANTH, Verrica is advancing VP-103, its second cantharidin-based product candidate, aimed at treating plantar warts. The company has broadened its dermatology therapeutic portfolio through a worldwide license agreement with Lytix Biopharma AS. This agreement focuses on the development and commercialization of VP-315 (previously known as LTX-315 and VP-LTX-315) for treating non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma.

This strategic focus on dermatology therapeutics highlights Verrica's commitment to addressing significant unmet needs in medical dermatology. The company's innovative approach and recent FDA approval of YCANTH® underscore its potential to make substantial contributions to the field.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!